Moderna and Merck Score Cancer Vaccine Win
Moderna and Merck report a historic success in late-stage trials for a personalized mRNA cancer vaccine in melanoma patients. The treatment successfully prevented tumor recurrence, marking a major milestone in oncology research.
Xurve View
Insights:
Xurve View